Texas Permanent School Fund Sells 2,226 Shares of Enovis Co. (NYSE:ENOV)

Posted by on May 13th, 2023

Texas Permanent School Fund cut its holdings in Enovis Co. (NYSE:ENOV – Get Rating) by 6.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,987 shares of the company’s stock after selling 2,226 shares during the quarter. Texas Permanent School Fund owned 0.06% of Enovis worth $1,712,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ENOV. Wipfli Financial Advisors LLC bought a new position in shares of Enovis during the 3rd quarter valued at $36,000. Godsey & Gibb Inc. bought a new position in shares of Enovis during the 4th quarter valued at $64,000. Seven Eight Capital LP bought a new position in shares of Enovis during the 3rd quarter valued at $210,000. Quantamental Technologies LLC bought a new position in shares of Enovis during the 3rd quarter valued at $221,000. Finally, Bank of Montreal Can bought a new position in shares of Enovis during the 4th quarter valued at $227,000. 96.73% of the stock is owned by institutional investors.

Enovis Trading Up 1.3 %

Shares of ENOV stock opened at $56.53 on Friday. Enovis Co. has a 52-week low of $43.88 and a 52-week high of $68.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.13 and a current ratio of 2.38. The firm has a market capitalization of $3.08 billion, a PE ratio of -58.89 and a beta of 2.01. The stock has a fifty day simple moving average of $54.76 and a two-hundred day simple moving average of $55.98.

Enovis (NYSE:ENOV – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Enovis had a positive return on equity of 3.70% and a negative net margin of 3.24%. The business had revenue of $406.20 million during the quarter, compared to analyst estimates of $389.95 million. During the same quarter in the prior year, the business posted $0.37 EPS. Enovis’s revenue for the quarter was up 8.2% compared to the same quarter last year. On average, analysts predict that Enovis Co. will post 2.2 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In other Enovis news, SVP Patricia A. Lang sold 545 shares of the stock in a transaction dated Tuesday, February 21st. The shares were sold at an average price of $62.11, for a total transaction of $33,849.95. Following the completion of the transaction, the senior vice president now owns 14,856 shares of the company’s stock, valued at approximately $922,706.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Enovis news, COO Brady Shirley sold 1,490 shares of the stock in a transaction dated Tuesday, February 21st. The shares were sold at an average price of $62.11, for a total transaction of $92,543.90. Following the completion of the transaction, the chief operating officer now owns 47,965 shares of the company’s stock, valued at approximately $2,979,106.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Patricia A. Lang sold 545 shares of the stock in a transaction dated Tuesday, February 21st. The shares were sold at an average price of $62.11, for a total transaction of $33,849.95. Following the transaction, the senior vice president now directly owns 14,856 shares of the company’s stock, valued at approximately $922,706.16. The disclosure for this sale can be found here. Insiders sold 65,881 shares of company stock valued at $3,738,005 in the last 90 days. Insiders own 5.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ENOV shares. Canaccord Genuity Group reissued a “buy” rating and set a $65.00 price target on shares of Enovis in a report on Tuesday, March 28th. Wells Fargo & Company upgraded Enovis from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $55.00 to $67.00 in a research note on Friday. Finally, Robert W. Baird upped their price objective on Enovis from $64.00 to $67.00 in a research note on Friday, May 5th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $64.88.

Enovis Company Profile

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Recommended Stories

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.